Novo Nordisk accepts Ozempic, Wegovy and Rybelsus prices in US Medicare negotiations

Core Point - Novo Nordisk has accepted the maximum fair price set by the U.S. Inflation Reduction Act (IRA) for its diabetes and obesity medications Ozempic, Wegovy, and Rybelsus, effective January 2027 [1] Company Summary - The acceptance of the IRA's pricing indicates a strategic alignment with U.S. healthcare policies, potentially impacting revenue streams for Novo Nordisk's diabetes and obesity drug portfolio [1] Industry Summary - The decision reflects broader trends in the pharmaceutical industry regarding pricing regulations and the impact of government policies on drug pricing and accessibility [1]